Language Selection

Get healthy now with MedBeds!
Click here to book your session

Protect your whole family with Orgo-Life® Quantum MedBed Energy Technology® devices.

Advertising by Adpathway

Cronus Pharma Launches First FDA-Approved Bioequivalent Robenacoxib Injection for Veterinary Use

2 hours ago 4

PROTECT YOURSELF with Orgo-Life® QUANTUM TECHNOLOGY

Orgo-Life the new way to the future

Advertising by Adpathway

Article content

First bioequivalent to ONSIOR^® (robenacoxib) Injection equips veterinarians with new, cost-effective NSAID (nonsteroidal anti-inflammatory) option for controlling postoperative pain and inflammation with certain surgical procedures in dogs and cats.

THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY

Subscribe now to read the latest news in your city and across Canada.

Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
Daily content from Financial Times, the world's leading global business publication.
Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
Daily puzzles, including the New York Times Crossword.

SUBSCRIBE TO UNLOCK MORE ARTICLES

Subscribe now to read the latest news in your city and across Canada.

Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
Daily content from Financial Times, the world's leading global business publication.
Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
Daily puzzles, including the New York Times Crossword.

Create an account or sign in to continue with your reading experience.

Access articles from across Canada with one account.
Share your thoughts and join the conversation in the comments.
Enjoy additional articles per month.
Get email updates from your favourite authors.

THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.

Create an account or sign in to continue with your reading experience.

Access articles from across Canada with one account
Share your thoughts and join the conversation in the comments
Enjoy additional articles per month
Get email updates from your favourite authors

Sign In or Create an Account

Article content

EAST BRUNSWICK, N.J. — Cronus Pharma LLC, a veterinary pharmaceutical company focused on developing high-quality, cost-effective animal health products, today announced the U.S. launch of Robenacoxib Injection, the only FDA-approved bioequivalent to ONSIOR^® (robenacoxib) Injection.

Article content

First bioequivalent to ONSIOR® (robenacoxib) Injection equips veterinarians with new, cost-effective NSAID (nonsteroidal anti-inflammatory) option for controlling postoperative pain and inflammation with certain surgical procedures in dogs and cats.

Article content

Robenacoxib Injection is indicated for the control of postoperative pain and inflammation associated with soft tissue surgery in dogs ≥ 4 months of age, and with orthopedic surgery, ovariohysterectomy and castration in cats ≥ 4 months of age; in each case for up to a maximum of 3 days. The product is now available for purchase through national and regional veterinary distributors across the United States.

Article content

By signing up you consent to receive the above newsletter from Postmedia Network Inc.

Article content

“Addressing post-operative pain is imperative in both dogs and cats,” said Scott A. Krick DVM – Consulting Technical Services Veterinarian at Cronus Pharma. “The launch of Robenacoxib Injection from Cronus Pharma provides a cost-effective NSAID option and reflects our commitment to expanding access to FDA-approved bioequivalent medications that support veterinarians, their patients, and pet owners.”

Article content

“The launch of Robenacoxib Injection marks an important addition to Cronus Pharma’s growing portfolio of FDA-approved veterinary products,” said Janel Fisher, Vice President of Sales at Cronus Pharma. “Innovation is at the heart of what we do, and we are continually looking for opportunities to bring meaningful new products to the veterinary market. This launch demonstrates our ability to turn that commitment to innovation into solutions that provide greater choice and value for the veterinary community.”

Article content

About Robenacoxib Injection:

Article content

Indicated for the control of postoperative pain and inflammation associated with soft tissue surgery in dogs ≥ 4 months of age, and with orthopedic surgery, ovariohysterectomy and castration in cats ≥ 4 months of age; in each case for up to a maximum of 3 days.
Available as a 20 mg/mL solution in a 20 mL multidose vial.
FDA approved as bioequivalent to the reference listed new animal drug, ONSIOR® (robenacoxib) Injection
Approved by FDA under ANADA # 200-804.

Article content

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use for more than three days, or in animals less than four months of age. Serious adverse events have been reported, including hepatopathy, with the long-term use (28-day study) of Robenacoxib tablets in dogs.

Article content

About Cronus Pharma

Article content

Based in East Brunswick, New Jersey, Cronus Pharma is a privately held veterinary generic pharmaceutical company dedicated to advancing animal health. With integrated research, development, manufacturing, and marketing, we deliver innovative and cost-effective solutions for animals. Our passionate team of scientists is actively developing new products, with a robust pipeline awaiting FDA approval. Cronus Pharma is committed to supporting veterinarians and pet owners with high-quality, accessible solutions.

Article content

Learn more about our mission to enhance animal health at www.cronuspharmausa.com.

Article content

ONSIOR Injection is a registered trademark of Elanco US Inc.

Article content